Edgewise Therapeutics, Inc.
EWTX
$44.17
$0.992.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 47.62M | 42.28M | 40.02M | 36.80M | 35.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.90M | 199.56M | 191.41M | 180.97M | 174.54M |
| Operating Income | -218.90M | -199.56M | -191.41M | -180.97M | -174.54M |
| Income Before Tax | -197.22M | -176.01M | -167.80M | -157.24M | -150.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -197.22 | -176.01 | -167.80 | -157.24 | -150.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -197.22M | -176.01M | -167.80M | -157.24M | -150.70M |
| EBIT | -218.90M | -199.56M | -191.41M | -180.97M | -174.54M |
| EBITDA | -216.77M | -197.45M | -189.32M | -178.83M | -172.39M |
| EPS Basic | -1.85 | -1.66 | -1.63 | -1.58 | -1.56 |
| Normalized Basic EPS | -1.16 | -1.04 | -1.02 | -0.99 | -0.97 |
| EPS Diluted | -1.85 | -1.66 | -1.63 | -1.58 | -1.56 |
| Normalized Diluted EPS | -1.16 | -1.04 | -1.02 | -0.99 | -0.97 |
| Average Basic Shares Outstanding | 426.29M | 423.56M | 411.58M | 400.29M | 388.61M |
| Average Diluted Shares Outstanding | 426.29M | 423.56M | 411.58M | 400.29M | 388.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |